The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice

Biochemical Pharmacology

Volumn 77, Issue 7, 2009, Pages 1151-1160

  Fritz, Wayne A ^a   Lin, Tien Min ^a   Safe, Stephen ^b   Moore, Robert W ^a   Peterson, Richard E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

6 MCDF; Metastasis inhibition; Prostate cancer; Selective aryl hydrocarbon receptor modulator; TRAMP mice; VEGF

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; AROMATIC HYDROCARBON RECEPTOR MODULATOR; EMODIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; LYMPH NODE METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTECTION;

ANIMALS; BENZOFURANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; ORGAN CULTURE TECHNIQUES; PELVIC NEOPLASMS; PROSTATIC NEOPLASMS; RECEPTORS, ARYL HYDROCARBON;

EID: 61449138610     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.12.015     Document Type: Article

References (46)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Institute of Medicine. Veterans and Agent Orange: update 2006. Washington, DC: National Academies Press; 2007.
3. Akhtar F.Z., Garabrant D.H., Ketchum N.S., and Michalek J.E. Cancer in US Air Force veterans of the Vietnam War. J Occup Environ Med 46 (2004) 123-136
4. Pavuk M., Michalek J.E., and Ketchum N.S. Prostate cancer in US Air Force veterans of the Vietnam War. J Expo Sci Environ Epidemiol 16 (2006) 184-190
5. Chamie K., deVere White R.W., Lee D., Ok J.-H., and Ellison L.M. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer. Cancer 113 (2008) 2464-2470
6. Fritz W.A., Lin T.-M., Moore R.W., Cooke P.S., and Peterson R.E. In utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure: effects on the prostate and its response to castration in senescent C57BL/6J mice. Toxicol Sci 86 (2005) 387-395
7. Kaplan-Lefko P.J., Chen T.M., Ittmann M.M., Barrios R.J., Ayala G.E., Huss W.J., et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55 (2003) 219-237
8. Shain S.A., McCullough B., and Segaloff A. Spontaneous adenocarcinomas of the ventral prostate of aged A × C rats. J Natl Cancer Inst 55 (1975) 177-180
9. Poland A., and Knutson J.C. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu Rev Pharmacol Toxicol 22 (1982) 517-554
10. Schmidt J.V., and Bradfield C.A. Ah receptor signaling pathways. Annu Rev Cell Dev Biol 12 (1996) 55-89
11. Lin T.-M., Ko K., Moore R.W., Simanainen U., Oberley T.D., and Peterson R.E. Effects of aryl hydrocarbon receptor null mutation and in utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on prostate and seminal vesicle development in C57BL/6 mice. Toxicol Sci 68 (2002) 479-487
12. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92 (1995) 3439-3443
13. Gingrich J.R., Barrios R.J., Morton R.A., Boyce B.F., DeMayo F.J., Finegold M.J., et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 56 (1996) 4096-4102
14. Gingrich J.R., Barrios R.J., Kattan M.W., Nahm H.S., Finegold M.J., and Greenberg N.M. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57 (1997) 4687-4691
15. Hsu C.X., Ross B.D., Chrisp C.E., Derrow S.Z., Charles L.G., Pienta K.J., et al. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urol 160 (1998) 1500-1505
16. Huss W.J., Hanrahan C.F., Barrios R.J., Simons J.W., and Greenberg N.M. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61 (2001) 2736-2743
17. Shappell S.B., Thomas G.V., Roberts R.L., Herbert R., Ittmann M.M., Rubin M.A., et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64 (2004) 2270-2305
18. Fritz W.A., Lin T.-M., and Peterson R.E. The aryl hydrocarbon receptor (AhR) inhibits prostate cancer progression in the TRAMP mouse. Carcinogenesis 28 (2007) 497-505
19. Jana N.R., Sarkar S., Ishizuka M., Yonemoto J., Tohyama C., and Sone H. Cross-talk between 2,3,7,8-tetrachlorodibenzo-p-dioxin and testosterone signal transduction pathways in LNCaP prostate cancer cells. Biochem Biophys Res Commun 256 (1999) 462-468
20. Chen I., McDougal A., Wang F., and Safe S. Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 19 (1998) 1631-1639
21. McDougal A., Sethi Gupta M., Ramamoorthy K., Sun G., and Safe S.H. Inhibition of carcinogen-induced rat mammary tumor growth and other estrogen-dependent responses by symmetrical dihalo-substituted analogs of diindolylmethane. Cancer Lett 151 (2000) 169-179
22. McDougal A., Wilson C., and Safe S. Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists. Cancer Lett 120 (1997) 53-63
23. Safe S., Qin C., and McDougal A. Development of selective aryl hydrocarbon receptor modulators for treatment of breast cancer. Expert Opin Investig Drugs 8 (1999) 1385-1396
24. Safe S., McDougal A., Gupta M.S., and Ramamoorthy K. Selective Ah receptor modulators (SAhRMs): progress towards development of a new class of inhibitors of breast cancer growth. J Women's Cancer 3 (2001) 37-45
25. Safe S., and McDougal A. Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers. Int J Oncol 20 (2002) 1123-1128
26. McDougal A., Wormke M., Calvin J., and Safe S. Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator. Cancer Res 61 (2001) 3902-3907
27. Koliopanos A., Kleeff J., Xiao Y., Safe S., Zimmermann A., Büchler M.W., et al. Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene 21 (2002) 6059-6070
28. Morrow D., Qin C., Smith III R., and Safe S. Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. J Steroid Biochem Mol Biol 88 (2004) 27-36
29. Astroff B., Zacharewski T., Safe S., Arlotto M.P., Parkinson A., Thomas P., and Levin W. 6-Methyl-1,3,8-trichlorodibenzofuran as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist: inhibition of the induction of rat cytochrome P-450 isozymes and related monooxygenase activities. Mol Pharmacol 33 (1988) 231-236
30. Lin T.M., Ko K., Moore R.W., Buchanan D.L., Cooke P.S., and Peterson R.E. Role of the aryl hydrocarbon receptor in the development of control and 2,3,7,8-tetrachlorodibenzo-p-dioxin-exposed male mice. J Toxicol Environ Health A 64 (2001) 327-342
31. Benedict J.C., Lin T.-M., Loeffler I.K., Peterson R.E., and Flaws J.A. Physiological role of the aryl hydrocarbon receptor in mouse ovary development. Toxicol Sci 56 (2000) 382-388
32. Fernandez-Salguero P., Pineau T., Hilbert D.M., McPhail T., Lee S.S., Kimura S., et al. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 268 (1995) 722-726
33. Schmidt J.V., Su G.H., Reddy J.K., Simon M.C., and Bradfield C.A. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci U S A 93 (1996) 6731-6736
34. Krijnen J.L., Janssen P.J., Ruizeveld de Winter J.A., van Krimpen H., Schroder F.H., and van der Kwast T.H. Do neuroendocrine cells in human prostate cancer express androgen receptor?. Histochemistry 100 (1993) 393-398
35. Harper M.E., Glynne-Jones E., Goddard L., Thurston V.J., and Griffiths K. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 74 (1996) 910-916
36. Borre M., Nerstrom B., and Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 6 (2000) 1882-1890
37. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
38. Ferrer F.A., Miller L.J., Andrawis R.I., Kurtzman S.H., Albertsen P.C., Laudone V.P., et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157 (1997) 2329-2333
39. Jones A., Fujiyama C., Turner K., Fuggle S., Cranston D., Bicknell R., et al. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int 85 (2000) 276-280
40. Safe S., and Wormke M. Inhibitory aryl hydrocarbon receptor-estrogen receptor α cross-talk and mechanisms of action. Chem Res Toxicol 16 (2003) 807-816
41. Dickerson R., Keller L.H., and Safe S. Alkyl polychlorinated dibenzofurans and related compounds as antiestrogens in the female rat uterus: structure-activity studies. Toxicol Appl Pharmacol 135 (1995) 287-298
42. Liu S., Abdelrahim M., Khan S., Ariazi E., Jordan V.C., and Safe S. Aryl hydrocarbon receptor agonists directly activate estrogen receptor α in MCF-7 breast cancer cells. Biol Chem 387 (2006) 1209-1213
43. Pearce S.T., Liu H., Radhakrishnan I., Abdelrahim M., Safe S., and Jordan V.C. Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran with estrogen receptor α. Cancer Res 64 (2004) 2889-2897
44. Mentor-Marcel R., Lamartiniere C.A., Eltoum I.E., Greenberg N.M., and Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 61 (2001) 6777-6782
45. Raghow S., Hooshdaran M.Z., Katiyar S., and Steiner M.S. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62 (2002) 1370-1376
46. Chetty R., and Weinreb I. Gastric neuroendocrine carcinoma arising from heterotopic pancreatic tissue. J Clin Pathol 57 (2004) 314-317